Phio Pharmaceuticals (PHIO) Research & Development (2011 - 2026)

Phio Pharmaceuticals (PHIO) has reported Research & Development for 16 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 186.96% year-over-year to $3.1 million; the trailing twelve-month figure through Jun 2026 stood at $8.5 million (up 137.75% YoY), and the FY2025 full-year result was $4.6 million, up 26.76% from the prior year.
• Research & Development grew to $3.1 million in Q2 2026 per PHIO's latest filing, from $2.8 million in the prior quarter.
• Across five years, Research & Development topped out at $3.1 million in Q2 2026 and bottomed at $644000.0 in Q3 2024.
• Historically, Research & Development has averaged $1.5 million across 5 years, with a median of $1.3 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Research & Development sank 64.38% in 2024, then surged 215.24% in 2026.
• Over 5 years, Research & Development stood at $1.6 million in 2022, then sank by 37.61% to $1.0 million in 2023, then slipped by 2.18% to $985000.0 in 2024, then surged by 49.95% to $1.5 million in 2025, then soared by 108.67% to $3.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $3.1 million, $2.8 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.